Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Accelerated Approval For PCSK9 Inhibitors Not Up For Discussion, FDA Tells Panel

Executive Summary

FDA asked its advisory committee not to discuss accelerated approval for Sanofi/Regeneron's Praluent and Amgen's Repatha; panelists wanted to discuss the idea anyway, however, given uncertainty around the reliability of LDL-cholesterol as a surrogate.

Advertisement

Related Content

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register